Novartis has launched its once-daily long-acting beta2 agonist Arcapta Neohaler (indacaterol inhalation powder) in the USA following its approval for...
Sunovion Pharma announces that it has entered into an exclusive agreement with Novartis for the US commercialization rights to three...
New results from a pooled post-hoc sub-group analysis from three studies (INVOLVE, INHANCE and INLIGHT2) showed that Onbrez Breezhaler/Arcapta Neohaler...
Novartis has filed a new drug application (NDA) at the FDA for once a day Seebri Breezhaler (NVA 237) (glycopyrronium...
The FDA has approved Seebri Neohaler (glycopyrrolate) inhalation powder 15.6 µg, from Novartis, as monotherapy for the long-term maintenance treatment...
The FDA has approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) inhalation powder, from Novartis, for the long-term maintenance treatment...
Novartis announced positive top-line results from the pivotal Phase III clinical trial programs for QVA 149 (indacaterol/glycopyrronium bromide) to support...
Novartis has announced the New England Journal of Medicine publication of the head-to-head FLAME study comparing the efficacy of once-daily...